Sorafenib and transarterial chemoembolization (TACE) might both provide survival benefit for advanced hepatocellular carcinoma (HCC). Adopting either as a first-line therapy carries major cost and resource implications. | Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma A costeffectiveness analysis